Publications by authors named "P Michael Peterson"
There is considerable variability in the management of common orofacial clefts across Europe, reflecting differing opinions on optimal treatments. An updated overview of treatment protocols for orofacial clefts across 26 expert centres in the European Reference Network CRANIO is presented here. A structured questionnaire was distributed to map the surgical protocol and additional standard procedures for cleft palate (CP), unilateral cleft lip and palate (UCLP), and bilateral cleft lip and palate (BCLP).
View Article and Find Full Text PDFWe identified two CRSwNP patients who had previously failed treatment with an anti-IL-4/IL-13 antibody (dupilumab). Based on their clinical characteristics and blood cytokine levels, we considered them mixed Type II/Type III cases and treated them with an anti-IL-17 antibody (secukinumab). Anti-IL-17 antibody secukinumab was superior in reducing their NPS and SNOT-22 values compared to dupilumab.
View Article and Find Full Text PDFImportance: Poor medication adherence is common. Text messaging is increasingly used to change patient behavior but often not rigorously tested.
Objective: To compare different types of text messaging strategies with usual care to improve medication refill adherence among patients nonadherent to cardiovascular medications.
Article Synopsis
- Recent advances in single-cell technology have allowed researchers to study age-related changes in the immune system more effectively, but inconsistent marker genes used in previous studies made comparisons difficult.
- This study combined over a million cells from 103 donors to create a unified atlas of immune cells, using consistent marker genes to classify both young and old individuals' immune systems.
- Key findings revealed trends such as a decrease in specific T cell populations with age and a heterogeneous nature of the T cell population linked to aging, highlighting the need for standardized datasets to better understand these changes.
Objectives: This study described real-world patient characteristics and outcomes among selpercatinib-treated patients in the United States, using the Flatiron Health electronic health record-derived deidentified database (FHD) for advanced/metastatic non-small cell lung cancer (a/mNSCLC) and Optum's de-identified Clinformatics Data Mart Database (CDM).
Methods: Patients initiating selpercatinib treatment between 08MAY2020 and 30JUN2023 were included. We evaluated real-world time to selpercatinib treatment discontinuation or death (rwTTDd) and time to next treatment or death (rwTTNTd) using Kaplan-Meier analyses.